Enbrel®, a tumor necrosis factor (TNF) blocker, is an FDA-approved RA therapeutic agent indicated for reducing signs and symptoms, inducing major clinical responses, inhibiting progression of structural damage, and improving physical function in patients with RA [44]. This evidence concerns the gene TNF and rheumatoid arthritis.